MX2021000700A - Composicion farmaceutica para prevenir o tratar esteatohepatitis no alcoholica. - Google Patents

Composicion farmaceutica para prevenir o tratar esteatohepatitis no alcoholica.

Info

Publication number
MX2021000700A
MX2021000700A MX2021000700A MX2021000700A MX2021000700A MX 2021000700 A MX2021000700 A MX 2021000700A MX 2021000700 A MX2021000700 A MX 2021000700A MX 2021000700 A MX2021000700 A MX 2021000700A MX 2021000700 A MX2021000700 A MX 2021000700A
Authority
MX
Mexico
Prior art keywords
preventing
nonalcoholic steatohepatitis
pharmaceutical composition
treating nonalcoholic
treating
Prior art date
Application number
MX2021000700A
Other languages
English (en)
Inventor
Jae-Sun Kim
Hyung-Chul Ryu
Jee-Woong Lim
Jung-Gun Joung
Sun-Joo Kim
Yeon-Woo Son
Hyung-Jun Kim
Wenling Song
Original Assignee
J2H Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J2H Biotech Inc filed Critical J2H Biotech Inc
Publication of MX2021000700A publication Critical patent/MX2021000700A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al uso médico de un compuesto, de fórmula química 1, para tratar, aliviar o prevenir esteatohepatitis no alcohólica (NASH) y/o fibrosis hepática. (ver Fórmula).
MX2021000700A 2018-07-23 2019-07-19 Composicion farmaceutica para prevenir o tratar esteatohepatitis no alcoholica. MX2021000700A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180085431A KR102177304B1 (ko) 2018-07-23 2018-07-23 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
PCT/KR2019/008963 WO2020022708A1 (ko) 2018-07-23 2019-07-19 비알콜성 지방간염의 예방 또는 치료용 약학 조성물

Publications (1)

Publication Number Publication Date
MX2021000700A true MX2021000700A (es) 2021-04-12

Family

ID=69181814

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000700A MX2021000700A (es) 2018-07-23 2019-07-19 Composicion farmaceutica para prevenir o tratar esteatohepatitis no alcoholica.

Country Status (11)

Country Link
US (1) US20210299127A1 (es)
EP (1) EP3827831A4 (es)
JP (1) JP7120691B2 (es)
KR (1) KR102177304B1 (es)
CN (1) CN112469415B (es)
AU (1) AU2019310474C1 (es)
BR (1) BR112021001130A2 (es)
CA (1) CA3107133C (es)
MX (1) MX2021000700A (es)
RU (1) RU2765101C1 (es)
WO (1) WO2020022708A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4247415A4 (en) 2021-01-29 2024-04-24 Curogen Tech Co Ltd PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LIVER DISEASES WITH SSU72
CN117412751A (zh) * 2021-06-01 2024-01-16 J2H生物科技有限公司 用于预防或治疗肺纤维化的药物制剂
KR20230027388A (ko) 2021-08-18 2023-02-28 제이투에이치바이오텍 (주) 지방간염, 지방증 또는 섬유증의 예방 또는 치료용 복합 제제
KR20240024419A (ko) 2022-08-16 2024-02-26 제이투에이치바이오텍 (주) 피리미딘-4-카복사마이드 화합물의 결정형 및 이를 포함하는 경구용 약학 제제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107383D0 (en) 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
MX360827B (es) * 2007-11-30 2018-11-16 Univ California Metodos para tratar la esteatohepatitis no alcoholica (nash) usando productos de cisteamina.
TW200936136A (en) * 2008-01-28 2009-09-01 Sanofi Aventis Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
FR2948370B1 (fr) * 2009-07-27 2013-04-05 Sanofi Aventis Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
KR20110123657A (ko) 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR101665009B1 (ko) * 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
FR3035326B1 (fr) * 2015-04-21 2017-05-12 Pf Medicament Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique
EP3278802A1 (en) * 2016-08-04 2018-02-07 Metabolys New treatment for the non alcoholic steatohepatitis and fibrosis

Also Published As

Publication number Publication date
EP3827831A1 (en) 2021-06-02
AU2019310474A1 (en) 2021-03-18
CN112469415A (zh) 2021-03-09
KR102177304B1 (ko) 2020-11-10
CA3107133C (en) 2023-06-20
AU2019310474B2 (en) 2023-02-09
EP3827831A4 (en) 2022-04-06
JP2021532187A (ja) 2021-11-25
JP7120691B2 (ja) 2022-08-17
WO2020022708A1 (ko) 2020-01-30
BR112021001130A2 (pt) 2021-04-20
CN112469415B (zh) 2024-04-16
CA3107133A1 (en) 2020-01-30
US20210299127A1 (en) 2021-09-30
KR20200010853A (ko) 2020-01-31
RU2765101C1 (ru) 2022-01-25
AU2019310474C1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
MX2021000700A (es) Composicion farmaceutica para prevenir o tratar esteatohepatitis no alcoholica.
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
MX2020011873A (es) Nuevos derivados de quinolina.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
EP3760626A4 (en) NEW COMPOUND AND COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF FIBROSIS OR NON-ALCOHOLIC STEATOHEPATITIS, INCLUDING IT AS AN ACTIVE SUBSTANCE
CA3042181C (en) Pharmaceutical composition for preventing and treating nonalcoholic steatohepatitis, hepatic fibrosis, and liver cirrhosis, comprising adenosine derivatives
ZA202006071B (en) Antiproliferation compounds and uses thereof
SG10201907291QA (en) Monomethylfumarate prodrug compositions
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2019012522A (es) Compuestos y metodos terapeuticos.
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
MX2019015849A (es) Nuevos compuestos de espirolactona.
MX2020001199A (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
MX2019004822A (es) Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo.
MX2020008082A (es) Compuestos y composiciones para el tratamiento del dolor.
MX2021005688A (es) Compuestos de piridina sulfonamida para el tratamiento contra afecciones relacionadas con interleucina 1 beta.
PH12018501100A1 (en) Phenylimidazole compound
PL3586832T3 (pl) Kompozycja farmaceutyczna do leczenia zaparcia
EP3863643A4 (en) AZD3355 (LESOGABERAN) FOR THE TREATMENT AND PREVENTION OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), HEPATIC FIBROSIS AND OTHER LIVER CONDITIONS